Retrospective evaluation of breast cancer patients with five or more axillary lymph node involvement achieving 5-year overall survival

Abstract

Objectives: The aim of this study was to analyze high risk breast cancer patients with involvement of five or more axillary lymph nodes with an overall survival of at least five years, and to determine the predictive and prognostic factors by comparing patients by recurrence/metastases status retrospectively.

Methods: From a total of 500 patients those were followed up in Adnan Menderes University, Medical Oncology department, 37 were eligible for the study; 23 were disease free and 14 had recurrence/metastases in the follow up period. The patients were analyzed, for demographical (such as age, menopausal status, obesity), anatomical and histological characteristics of tumor (primary tumor’s diameter, stage, grade, Ki-67, hormon receptors and Her-2 status), treatment modalities and prognosis.

Results: Both number of metastatic lymph nodes and (metastatic/sampled) lymph node ratio were not significantly different between the recurrence-free and metastatic patients. In the recurrence-free patients both grade 3 (48% vs none, p = 0.03) and p53 negative tumors (64% vs 36%, p = 0.036) were significantly more than metastatic patients. Also in the recurrence free patients as compared to metastatic patients, adjuvant chemotherapy was applied more than 6 cycles (87% vs 43%, p = 0.004), the regimens included more taxane based regimens (91% vs 64%, p = 0.042), aromatase inhibitors were used higher (100% vs 75%, p = 0.019) and the period of tamoxifen treatment in switch regimens were shorter.

Conclusion: The results of this study suggested that, high risk breast cancer patients with involvement of five and more nodes that have the predictive factors as grade 3 and/or p53 negative tumors are propably more responsive to adjuvant treatments. Chemotherapy of more than 6 cycles, administering taxane based regimens and aromatase inhibitors in the adjuvant regimens may favourably effect the prognosis.

Keywords

• breast cancer,lymph node metastases,predictive and prognostic factors

References

1. [1] Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol 2014;5:412-2.
2. [2] National Comprehensive Cancer Network. Breast Cancer (Version 3.2017). Avaible from https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
3. [3] Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol 2017. doi: 10.1016/j.semcancer.2017.08.010.
4. [4] Kawai M, Minami Y, Kuriyama S, Kakizaki M, Kakugawa Y, Nishino Y, et al. Adiposity, adult weight change and breast cancer risk in postmenopausal Japanese women: the Miyagi Cohort Study. Br J Cancer 2010;103:1443-7.
5. [5] Li CI, Malone KE, Daling JR, Potter JD, Bernstein L, Marchbanks PA, et al. Timing of menarche and first full-term birth in relation to breast cancer risk. Am J Epidemiol 2008;167:230-9.
6. [6] Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358-66.
7. [7] Zhang SM, Lee IM, Manson JE, Cook NR, Willett WC, Buring JE. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol 2007;165:667-76.
8. [8] Islam T, Matsuo K, Ito H, Hosono S, Watanabe M, Iwata H, et al. Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women. Ann Oncol 2012;23:2435-41.

9. [9] Hartmann LC, Radisky DC, Frost MH, Santen RJ, Vierkant RA, Benetti LL, et al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila) 2014;7:211-7.
10. [10] Shien T, Kinoshita T, Seki K, Yoshida M, Hojo T, Shimizu C, et al. p53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancer. Acta Med Okayama 2013;67:165-70.
11. [11] Karatas F, Sahin S, Erdem GU, Ates O, Babacan T, Akin Set al. Left laterality is an independent prognostic factor for metastasis in N3 stage breast cancer. J BUON. 2016;21:851-8.
12. [12] Rosen PP, Groshen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993;11:2090-100.
13. [13] Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
14. [14] Dings PJ, Elferink MA, Strobbe LJ, de Wilt JH. The prognostic value of lymph node ratio in node-positive breast cancer: a Dutch nationwide population-based study. Ann Surg Oncol 2013;20:2607-14.
15. [15] Nabholtz JM1, Gligorov J. The role of taxanes in the treatment of breast cancer. Expert Opin Pharmacother 2005;6:1073-94.